1). Pouchot J., Sampalis JS., Beaudet F., Carette S., Decary F., Salusinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991. 70:118–36.
2). Coghlan JG., Handler C. Connective tissue associated pulmonary arterial hypertension. Lupus. 2006. 15:138–42.
Article
3). Mubashir E., Ahmed MM., Hayat S., Heldmann M., Berney SM. Pulmonary hypertension in a patient with adult-onset stills disease. Clin Rheumatol. 2006.
Article
4). Zen A., Yamashita N., Ueda M., Asakawa Y., Yoshikawa Y., Funai T, et al. A case of adult Still's disease with pulmonary hypertension. Ryumachi. 1990. 30:45–52.
5). Magliano M., Isenberg DA., Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? Arthritis Rheum. 2002. 46:1997–2009.
Article
6). Tuder RM., Groves B., Badesch DB., Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994. 144:275–85.
7). Eddahibi S., Humbert M., Sediame S., Chouaid C., Partovian C., Maitre B, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respi Crit Care Med. 2000. 162:1493–9.
8). Humbert M., Monti G., Brenot F., Sitbon O., Portier A., Grangeot-Keros L, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995. 151:1628–31.
Article
9). Shen JY., Chen SL., Wu YX., Tao RQ., Gu YY., Bao CD, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int. 1999. 18:147–51.
Article
10). Dantzker DR. Primary pulmonary hypertension. The American experience. Chest. 1994. 105((Suppl):):26S–8S.
11). Rich S., Kaufmann E., Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. New Engl J Med. 1992. 327:76–81.
Article
12). Sanchez O., Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax. 1999. 54:273–7.
Article
13). 최혜숙: 이상도. 폐동맥고혈압에서폐혈관계작용약물. 결핵및호흡기질환. 2006. 60:142–50.
14). Wilkens H., Guth A., Konig J., Forestier N., Cremers B., Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001. 104:1218–22.
Article
15). Channick RN., Simonneau G., Sitbon O., Robbins IM., Frost A., Tapson VF, et al. Effects of the dual endo-thelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001. 358:1119–23.
Article